Stem Cells International

Clinical Study

Combination Treatments of Plasma Exchange and Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Clinical Trial in China

Table 3

Independent variables associated with unfavorable outcomes with logistic regression after modeling and adjusting covariates by GEE models.


	Univariate		Multivariate
Parameters	OR (95% CI)	value	OR (95% CI)	value

UC-MSC treated
No	ref	—	ref	—
Yes	0.73 (0.43-1.22)	0.229¹	0.88 (0.49-1.56)	0.653
PE treated
No	ref	—	ref	—
Yes	0.82 (0.49-1.38)	0.463¹	0.64 (0.36-1.13)	0.124
Age, year	1.03 (1.00-1.06)	0.050	1.02 (0.99-1.06)	0.179
Sex
Male	ref	—
Female	0.86 (0.22-3.42)	0.828
Complications
No	ref	—	ref	—
Yes	2.18 (1.25-3.81)	0.006	1.09 (0.59-2.02)	0.776
WBC, 10⁹/L	1.16 (1.07-1.27)	<0.001	1.03 (0.89-1.19)	0.663
N%	1.05 (1.02-1.08)	<0.001	1.02 (0.99-1.06)	0.200
RBC, 10¹²/L	1.02 (0.99-1.06)	0.225
Hemoglobin, g/L	0.98 (0.97-0.99)	<0.001	0.98 (0.97-1.00)	0.035
Platelet, 10⁹/L	1.00 (0.99-1.00)	0.279
AST, U/L	1.00 (1.00-1.00)	0.033	1.00 (1.00-1.00)	0.097
ALT, U/L	1.00 (1.00-1.00)	0.219
Albumin, g/L	1.00 (1.00-1.01)	0.173
Cholinesterase, U/L	1.00 (1.00-1.00)	0.367
TBIL, μmol/L	1.00 (1.00-1.01)	<0.001²
Creatinine, μmol/L	1.01 (1.01-1.02)	0.001²
Prothrombin time, sec.	1.06 (0.97-1.16)	0.172
Prothrombin activity, %	0.88 (0.84-0.91)	<0.001	0.93 (0.87-0.98)	0.010
INR	2.24 (1.49-3.38)	<0.001²
MELD score	1.23 (1.16-1.31)	<0.001	1.12 (1.03-1.22)	0.008

¹Patients being treated with UC-MSC or/and PE would be entered into a multivariate model even if it was not significant in univariate results. ²TBIL, creatinine, and INR would not be included in the multivariate model because the MELD score was calculated by these three indexes to prevent multicollinearity. UC-MSC, umbilical cord-derived mesenchymal stem cells; PE, plasma exchange; WBC, white blood cells; RBC, red blood cells; AST, aspartate aminotransferase; ALT, alanine transaminase; TBIL, total bilirubin; INR, international normalized ratio; MELD, model for end-stage liver disease.